• Clover Health Investments held its annual shareholder meeting on June 10, 2026.
• Shareholders selected Demetrios L. Kouzoukas, Andrew Toy, Thomas L. Tran as Class II directors, with terms running to the 2029 annual meeting.
• Shareholders backed a non-binding advisory resolution on executive pay for 2025.
• Shareholders ratified Ernst & Young as independent registered public accounting firm for the year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clover Health Investments Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001801170-26-000148), on June 12, 2026, and is solely responsible for the information contained therein.